Merck Announces New FDA-Approved Guidelines for HPV Vaccine

Spread the love


The vaccine prevents oral cancer caused by HPV types (16, 18, 31, 33, 45, 52 and 58), precancerous or dysplastic lesions caused by HPV types (6, 11, 16, 18, 31, 33, 45, 52 and 58) and genital warts caused by HPV types 6 and 11.

‘GARDASIL 9, Merck’s Human Papilloma Vaccine can now be administered to males from 16 through 26 years of age to prevent oral cancer, precancerous lesions and genital warts.’



GARDASIL 9 has been already approved by the USFDA for use in boys 9 through 15 years of age for the prevention of these diseases. Similarly, the vaccine can prevent cervical, vulvar, vaginal, and anal cancers caused by HPV types when administered to girls and young women 9 through 26 years of age.

GARDASIL 9 is contraindicated in individuals with hypersensitivity, including severe allergic reactions to yeast, or after a previous dose of GARDASIL 9 or GARDASIL [Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) Vaccine, Recombinant].

Source: Medindia



Source link

Related Posts

Leave a Reply

Your email address will not be published. Required fields are marked *

indian fitness care